PortfoliosLab logo
AlloVir, Inc. (ALVR)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US0198181036

CUSIP

019818103

IPO Date

Jul 30, 2020

Highlights

Market Cap

$49.48M

EPS (TTM)

-$11.73

EBITDA (TTM)

-$32.94M

Year Range

$7.96 - $24.15

Target Price

$1.20

Short %

2.01%

Short Ratio

3.08

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in AlloVir, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%100.00%Nov 10Nov 17Nov 24DecemberDec 08Dec 15Dec 22Dec 29Jan 05Jan 12Jan 19Jan 26Feb 02Feb 09Feb 16Feb 23Mar 02Mar 09Mar 16
-98.04%
74.83%
ALVR (AlloVir, Inc.)
Benchmark (^GSPC)

Returns By Period


ALVR

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-4.26%

1M

11.24%

6M

-5.02%

1Y

8.55%

5Y*

14.02%

10Y*

10.31%

*Annualized

Monthly Returns

The table below presents the monthly returns of ALVR, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-2.48%4.03%17.04%18.74%
20245.88%2.36%2.44%5.17%-4.91%-4.24%2.49%5.13%3.85%14.96%-41.08%-23.36%-38.24%
202312.67%16.78%-41.63%-12.69%9.59%-9.81%-3.24%-4.86%-31.31%-30.23%25.33%-63.83%-86.74%
2022-36.94%10.29%-25.00%-32.59%-14.95%0.78%17.69%63.62%5.06%-12.17%8.37%-31.69%-60.36%
2021-4.86%-0.03%-36.00%0.98%-0.80%-15.78%-3.04%0.57%30.18%-4.19%-27.28%-25.89%-66.34%
2020-1.93%30.08%-15.10%-3.89%49.87%-2.95%51.40%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ALVR is 31, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of ALVR is 3131
Overall Rank
The Sharpe Ratio Rank of ALVR is 2828
Sharpe Ratio Rank
The Sortino Ratio Rank of ALVR is 3333
Sortino Ratio Rank
The Omega Ratio Rank of ALVR is 3232
Omega Ratio Rank
The Calmar Ratio Rank of ALVR is 3131
Calmar Ratio Rank
The Martin Ratio Rank of ALVR is 2828
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for AlloVir, Inc. (ALVR) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


There is not enough data available to calculate the Sharpe ratio for AlloVir, Inc.. We calculate this metric based on the past 12 months of trading data. Please check back later for updated information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00Nov 10Nov 17Nov 24DecemberDec 08Dec 15Dec 22Dec 29Jan 05Jan 12Jan 19Jan 26Feb 02Feb 09Feb 16Feb 23Mar 02Mar 09Mar 16
-0.45
0.70
ALVR (AlloVir, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


AlloVir, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%Nov 10Nov 17Nov 24DecemberDec 08Dec 15Dec 22Dec 29Jan 05Jan 12Jan 19Jan 26Feb 02Feb 09Feb 16Feb 23Mar 02Mar 09Mar 16
-98.93%
-7.63%
ALVR (AlloVir, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the AlloVir, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the AlloVir, Inc. was 99.19%, occurring on Jan 15, 2025. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.19%Dec 7, 20201032Jan 15, 2025
-50.7%Aug 12, 202024Sep 15, 202056Dec 3, 202080
-1.93%Jul 31, 20201Jul 31, 20201Aug 3, 20202

Volatility

Volatility Chart

The current AlloVir, Inc. volatility is 23.97%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%Nov 10Nov 17Nov 24DecemberDec 08Dec 15Dec 22Dec 29Jan 05Jan 12Jan 19Jan 26Feb 02Feb 09Feb 16Feb 23Mar 02Mar 09Mar 16
23.97%
5.86%
ALVR (AlloVir, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of AlloVir, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of AlloVir, Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 60.2% positive surprise.


-4.00-3.00-2.00-1.000.0020212022202320242025
-3.64
-0.16
Actual
Estimate

Valuation

The Valuation section provides an overview of how AlloVir, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for ALVR relative to other companies in the Biotechnology industry. Currently, ALVR has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for ALVR in comparison with other companies in the Biotechnology industry. Currently, ALVR has a P/B value of 0.4. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items